CN107898920A - 一种用于糖尿病的口含制品与制备方法 - Google Patents
一种用于糖尿病的口含制品与制备方法 Download PDFInfo
- Publication number
- CN107898920A CN107898920A CN201711175472.0A CN201711175472A CN107898920A CN 107898920 A CN107898920 A CN 107898920A CN 201711175472 A CN201711175472 A CN 201711175472A CN 107898920 A CN107898920 A CN 107898920A
- Authority
- CN
- China
- Prior art keywords
- mushroom
- raw
- pharmaceutical chemicals
- bulk pharmaceutical
- ophiopogon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 title description 6
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 78
- 239000000126 substance Substances 0.000 claims abstract description 48
- 239000003814 drug Substances 0.000 claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 43
- 238000000855 fermentation Methods 0.000 claims abstract description 39
- 230000004151 fermentation Effects 0.000 claims abstract description 38
- 239000007788 liquid Substances 0.000 claims abstract description 34
- 241000894007 species Species 0.000 claims abstract description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000001257 hydrogen Substances 0.000 claims abstract description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 32
- 229930195210 Ophiopogon Natural products 0.000 claims abstract description 30
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 29
- 241000512259 Ascophyllum nodosum Species 0.000 claims abstract description 28
- 241000287828 Gallus gallus Species 0.000 claims abstract description 28
- 241000241413 Propolis Species 0.000 claims abstract description 28
- 241000405414 Rehmannia Species 0.000 claims abstract description 28
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 28
- 239000006286 aqueous extract Substances 0.000 claims abstract description 28
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 28
- 229940069949 propolis Drugs 0.000 claims abstract description 28
- 241001474374 Blennius Species 0.000 claims abstract description 27
- 241001165494 Rhodiola Species 0.000 claims abstract description 27
- 244000269722 Thea sinensis Species 0.000 claims abstract description 27
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 27
- 210000004317 gizzard Anatomy 0.000 claims abstract description 27
- 239000012528 membrane Substances 0.000 claims abstract description 27
- 239000009636 Huang Qi Substances 0.000 claims abstract description 26
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 26
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 26
- 238000001467 acupuncture Methods 0.000 claims abstract description 24
- 240000006794 Volvariella volvacea Species 0.000 claims abstract description 19
- 239000003643 water by type Substances 0.000 claims abstract description 11
- 238000000605 extraction Methods 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 239000002904 solvent Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 150000004676 glycans Chemical class 0.000 claims description 18
- 229920001282 polysaccharide Polymers 0.000 claims description 18
- 239000005017 polysaccharide Substances 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 9
- 238000001556 precipitation Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 241000219780 Pueraria Species 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 3
- 239000002893 slag Substances 0.000 claims description 2
- 241001448424 Ophiopogon Species 0.000 claims 10
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims 2
- 150000001298 alcohols Chemical class 0.000 claims 1
- 238000011026 diafiltration Methods 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 238000010792 warming Methods 0.000 claims 1
- 238000003809 water extraction Methods 0.000 claims 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract description 22
- 208000024891 symptom Diseases 0.000 abstract description 15
- 210000004369 blood Anatomy 0.000 description 47
- 239000008280 blood Substances 0.000 description 47
- 239000000047 product Substances 0.000 description 47
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 33
- 239000008103 glucose Substances 0.000 description 33
- 230000007812 deficiency Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 210000003734 kidney Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 201000010099 disease Diseases 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 10
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 10
- 229920002527 Glycogen Polymers 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 229940096919 glycogen Drugs 0.000 description 9
- 230000002440 hepatic effect Effects 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 229940090044 injection Drugs 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 8
- 201000001421 hyperglycemia Diseases 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 229960003243 phenformin Drugs 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000035922 thirst Effects 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 208000012287 Prolapse Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000004153 islets of langerhan Anatomy 0.000 description 4
- 238000009629 microbiological culture Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 3
- 239000004366 Glucose oxidase Substances 0.000 description 3
- 206010023379 Ketoacidosis Diseases 0.000 description 3
- 208000007976 Ketosis Diseases 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 206010053615 Thermal burn Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000001142 anti-diarrhea Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 201000005917 gastric ulcer Diseases 0.000 description 3
- 229940116332 glucose oxidase Drugs 0.000 description 3
- 235000019420 glucose oxidase Nutrition 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 206010001580 Albuminuria Diseases 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 235000002722 Dioscorea batatas Nutrition 0.000 description 2
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 2
- 240000001811 Dioscorea oppositifolia Species 0.000 description 2
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000234280 Liliaceae Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010030124 Oedema peripheral Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 208000020670 canker sore Diseases 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000001114 myogenic effect Effects 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000009931 pascalization Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000022558 protein metabolic process Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 241001147461 Bangiales Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000010837 Diabetic eye disease Diseases 0.000 description 1
- 241000234272 Dioscoreaceae Species 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 240000005739 Eurycoma longifolia Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241001537207 Flammulina Species 0.000 description 1
- -1 Flavone compound Chemical class 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 241000726221 Gemma Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241001492261 Pleurotaceae Species 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 241000206609 Porphyra Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- YUGCAAVRZWBXEQ-UHFFFAOYSA-N Precholecalciferol Natural products C=1CCC2(C)C(C(C)CCCC(C)C)CCC2C=1C=CC1=C(C)CCC(O)C1 YUGCAAVRZWBXEQ-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- 235000003713 Rhodiola rosea Nutrition 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- 241000736078 Schisandra sphenanthera Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 241001507667 Volvariella Species 0.000 description 1
- 235000004501 Volvariella volvacea Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000746966 Zizania Species 0.000 description 1
- 235000002636 Zizania aquatica Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000008445 altitude sickness Diseases 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000001716 anti-fugal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明“一种用于糖尿病的口含制品,中药组合物及其制备方法”,属于中医药领域,其特征在于是以下原料药的水提取液与香菇、草菇和金针菇母种液进行共发酵所得的产物;所述原料药具有以下重量份配比:红景天15‑25,蜂胶8‑12,东革阿里80‑100,海带8‑12,紫菜8‑12,金针菇子实体8‑12,茶树菇子实体8‑12,葛根8‑12,生黄芪8‑12,生山药8‑12,花粉8‑12,知母8‑12,五味子8‑12,生鸡内金8‑12,麦冬8‑12,生地8‑12;所述原料药的水提取液采用富氢水优选日田天领水为提取溶剂;所述口含制品在能够显著改善糖尿病症状。
Description
技术领域
本发明涉及中医制品及其加工技术,特别是涉及用于糖尿病的口含制品与制备方法。
技术背景
糖尿病(diabetes mellitus)是一种体内胰岛素相对或绝对不足或靶细胞对胰岛素敏感性降低,或胰岛素本身存在结构上的缺陷而引起的碳水化合物、脂肪和蛋白质代谢紊乱的一种慢性疾病。其主要特点是高血糖、糖尿。临床上表现为多饮、多食、多尿和体重减少(即“三多一少”),可使一些组织或器官发生形态结构改变和功能障碍,并发酮症酸中毒、肢体坏疽、多发性神经炎、失明和肾功能衰竭等。糖尿病时长期存在的高血糖,导致各种组织,特别是眼、肾、心脏、血管、神经的慢性损害、功能障碍。本病发病率日益增高,已成为世界性的常见病、多发病。
中医学对本病的病因病机论述较为详细,认为主要是由于素体阴虚,五脏柔弱,复因饮食不节,过食肥甘,情志失调,劳欲过度,而导致肾阴亏虚,肺胃燥热;病机重点为阴虚燥热,而以阴虚为本,燥热为标;病延日久,阴损及阳,阴阳俱虚;阴虚燥热,耗津灼液使血液粘滞,血行涩滞而成瘀。
糖尿病的诊断不难,空腹血糖大于或等于7.0毫摩尔/升,和/或餐后两小时血糖大于或等于11.1毫摩尔/升即可确诊。诊断糖尿病后要进行分型:1型糖尿病
发病年龄轻,大多小于30岁,起病突然,多饮多尿多食消瘦症状明显,血糖水平高,不少患者以酮症酸中毒为首发症状,血清胰岛素和C肽水平低下,ICA、IAA或GAD抗体可呈阳性。单用口服药无效,需用胰岛素治疗。2型糖尿病,常见于中老年人,肥胖者发病率高,常可伴有高血压,血脂异常、动脉硬化等疾病。起病隐袭,早期无任何症状,或仅有轻度乏力、口渴,血糖增高不明显者需做糖耐量试验才能确诊。血清胰岛素水平早期正常或增高,晚期低下。
糖尿病如果久治不愈,病情控制不好,容易发生急、慢性并发症,波及全身各个器官、组织,例如低血糖、糖尿并酮症酸中毒、乳酸中毒、心脑血血管病变、脂肪肝、糖尿病足、糖尿病眼病、微循环障碍等,严重影响正常生活。
发明内容
基于上述领域的需求,本发明提供一种用于糖尿病的口含制品及其制备工艺,可用于预防和治疗糖尿病及其并发症。
一种用于糖尿病的口含制品,其特征在于:
是以下原料药的水提取液与香菇、草菇、金针菇母种液进行共发酵所得的产物;
所述原料药具有以下重量份配比:红景天15-25,蜂胶8-12,东革阿里80-110,海带8-12,紫菜8-12,金针菇子实体8-12,茶树菇子实体8-12,葛根8-12,生黄芪8-12,生山药8-12,花粉8-12,知母8-12,五味子8-12,生鸡内金8-12,麦冬8-12,生地8-12。
所述原料药的水提取液是采用富氢水为提取溶剂,所述富氢水为日田天领水。
优选地,所述原料药具有以下任一组重量份配比:
红景天20、蜂胶10,东革阿里100,海带10,紫菜10,金针菇子实体10,茶树菇子实体10,葛根10,生黄芪10,生山药10,花粉10,知母10,五味子10,生鸡内金10,麦冬10,生地10;
红景天15,蜂胶12,东革阿里80,海带12,紫菜12,金针菇子实体8,茶树菇子实体12,葛根8,生黄芪8,生山药10,花粉10,知母12,五味子8,生鸡内金12,麦冬9,生地10;
红景天25,蜂胶8,东革阿里110,海带8,紫菜8,金针菇子实体12,茶树菇子实体10,葛根10,生黄芪12,生山药8,花粉8,知母8,五味子10,生鸡内金8,麦冬8,生地8;
红景天18,蜂胶9,东革阿里90,海带9,紫菜9,金针菇子实体9,茶树菇子实体8,葛根12,生黄芪9,生山药12,花粉12,知母10,五味子12,生鸡内金9,麦冬9,生地12。
一种用于制备糖尿病口含制品的原料组合物,其特征在于:包括A原料药,具有以下重量份配比:红景天15-25,蜂胶8-12,东革阿里80-110,海带8-12,紫菜8-12,金针菇子实体8-12,茶树菇子实体8-12,葛根8-12,生黄芪8-12,生山药8-12,花粉8-12,知母8-12,五味子8-12,生鸡内金8-12,麦冬8-12,生地8-12。
所述A原料药,具有以下任一组重量份配比:
红景天20、蜂胶10,东革阿里100,海带10,紫菜10,金针菇子实体10,茶树菇子实体10,葛根10,生黄芪10,生山药10,花粉10,知母10,五味子10,生鸡内金10,麦冬10,生地10;
红景天15,蜂胶12,东革阿里80,海带12,紫菜12,金针菇子实体8,茶树菇子实体12,葛根8,生黄芪8,生山药10,花粉10,知母12,五味子8,生鸡内金12,麦冬9,生地10;
红景天25,蜂胶8,东革阿里110,海带8,紫菜8,金针菇子实体12,茶树菇子实体10,葛根10,生黄芪12,生山药8,花粉8,知母8,五味子10,生鸡内金8,麦冬8,生地8;
红景天18,蜂胶9,东革阿里90,海带9,紫菜9,金针菇子实体9,茶树菇子实体8,葛根12,生黄芪9,生山药12,花粉12,知母10,五味子12,生鸡内金9,麦冬9,生地12。
上述任一用于糖尿病的口含制品的制备方法,包括如下步骤:
(1)制备原料药的水提取液;
(2)原料药的水提取液与香菇母种液、草菇母种液和金针菇母种液进行共发酵得到发酵产物;
其特征在于,所述原料药的水提取液的提取工艺如下:在提取容器中,加入富氢水和原料药;富氢水与所述原料药重量比例为3-6:1,在25-35℃、800mpa环境下提取30-50分钟得到所述原料药的水提取液。
优选地,富氢水与所述原料药重量比例为4-5:1,在28-32℃、800mpa环境下提取30-40分钟得到所述原料药的水提取液。
优选地,所述进行共发酵是指在发酵罐中,按30-50:30-50:5-10:5-10:5-10的体积比加入所述原料药的水提取液、富氢水、香菇母种液、草菇母种液和金针菇母种液,发酵到有效固体物含量达80g/L以上时放罐。
优选地,按35-45:35-45:6-8:6-8:6-8的体积比加入所述原料药的水提取液、富氢水、香菇母种液、草菇母种液和金针菇母种液。
优选地,发酵结束放罐后,发酵产物进入醇沉提取罐,用冷水浸提渗滤,将提取液沉淀,利用多糖不溶于乙醇的性质,在≦30℃低温下浸制5小时,使多糖从提取液中沉淀出来,对沉淀再进行≦55℃烘干或喷雾干燥得成品。
发明人经研究,根据中医对糖尿病病因的历史传承结论,中药用药的配伍思想,在配伍出的中药原料药基础上,创造性地采用共同发酵的方法联合使用食用菌,通过发酵使得食用菌中的多糖、中药材中的植物多糖的比例大大提高,同时使中药材中其它有效成分分离出来,植物多糖和食用菌多糖协同温和地作用于患者糖代谢系统,使患者碳水化合物、脂肪和蛋白质代谢恢复平衡,提高胰岛素分泌水平,缓解糖尿病及其并发症。
所谓含,即舌下含服十分钟,其有效物已由口腔粘膜吸收,避免了胃酸对其分解而部份失去。其渣可吐可纳。
本发明的制品在制备过程中所用的水为富氢水,富氢水是最好的抗氧化物,集高氢量、弱碱性、负电位、小份子水为一体,容易在细胞膜穿梭参与新陈代谢,从而促进细胞排毒,增加了细胞的水合作用。使用富氢水使本发明的口含制品具有很强的还原功能,可以中和身体血液和细胞里的活性氧(自由基),平衡身体酸碱度,能促进机体微循环水平,修复因糖尿病并发症引起的各种细胞/组织损伤,并可有效缓解或预防多种并发症。
本发明的另一个主要的贡献在于,还提供了专门针对本发明的口含制品的制备方法,采用富氢水作为溶剂,在常温、超高压(30℃、800mpa)下提取中药成分,能够最大限度地将中药材植物细胞壁内容物提取出来,并保持原有成分和分子结构从而保留药效与原料药基本一致。
本发明的口含制品中采用的中药材中多种成分共奏扶正固本,强补全身之气,护肝、肾和心血管,提高免疫力之功效,有利于预防和治疗糖尿病及其并发症的各种症状。采用的原料药药理如下:
红景天:Rhodiola rosea L,多年生草本植物,补气清肺,益智养心,收涩止血,散瘀消肿。主治气虚体弱,气短乏力,肺热咳嗽,跌打损伤,烫火伤,神经症,高原反应;可调节新陈代谢、神经乏力等;散瘀消肿,维生素A、D、E和抗衰老活性超氧化物,也用于病后体虚。
蜂胶:蜂胶是蜜蜂从植物芽孢或树干上采集的树脂,将其混入其上腭腺、蜡腺的分泌物加工而成的一种具有芳香气味的胶状固体物。其性平,味苦、辛、微甘,有润肤生肌,消炎止痛的功效,可治疗胃溃疡、口腔溃疡、烧烫伤、皮肤裂痛,防辐射等病症。
东革阿里,拉丁学名:Eurycoma longifolia,是生长在东南亚靠近赤道的原始热带雨林中潮湿砂质土壤里的一种野生灌木植物的根。促进人体分泌更多的荷尔蒙、雄性激素、黄体酮等,可调节人体内分泌、使人体自身阴阳平衡、增强血液循环和新陈代谢,增加肾动力。
海带:别名昆布、江白菜,褐藻门海带属的一种可食用的藻类,其味咸、性寒;入肝、胃、肾、肺经。可软坚化痰,祛湿止痒,清热行水。
紫菜:Porphyra,红藻纲,红毛菜科,具有化痰软坚、清热利水、补肾养心的功效。
茶树菇子实体:原为江西广昌境内高山密林地区茶树蔸部生长的一种野生蕈菌,是集高蛋白,低脂肪,低糖分,保健食疗于一身的纯天然无公害保健食用菌。具有补肾、利尿、治腰酸痛、渗湿、健脾、止泻等功效,是高血压、心血管和肥胖症患者的理想食品。
葛根:为豆科植物野葛的根,葛根有生津止渴、止泻的功能,能降低血糖,并有解热及雌激素样作用并能改善高血压糖尿病病人的头晕、头痛等症状。
生黄芪:为豆科植物蒙古黄芪或膜荚黄芪的根,味甘,微温,具有补气固表,托疮生肌、利水的功效,主治气血虚弱、自汗、久泻脱肛、子宫脱垂、肾炎浮肿、蛋白尿、糖尿病、慢性溃疡等症,临床用来治疗高血压和急慢性肾炎。
生山药:药用来源为薯蓣科植物山药干燥根茎。具有滋养强壮,助消化,敛虚汗,止泻之功效,主治脾虚腹泻、肺虚咳嗽、糖尿病消渴、小便短频、遗精、妇女带下及消化不良的慢性肠炎。
花粉:是种子植物的微小孢子堆,被营养学家称为“全能的营养库,增强人体综合免疫功能:花粉多糖能激活巨噬细胞的吞噬活动,提高人体抗病能力,花粉中的VE、超氧化歧化酶(SOD)、硒等成分能滋润营养肌肤,恢复皮肤的弹性和光洁。花粉中的肌醇可使白发变黑,脱发渐生,保持头发乌黑亮丽。防治脑心血管疾病:花粉中的黄酮类化合物能有效清除血管壁上脂肪的沉积,从而起软化血管和降血脂的作用。
知母:为单子叶植物百合科知母的干燥根茎。归肺、胃、肾经;清热泻火,滋阴润燥。主治:热病烦渴,肺热燥咳,骨蒸潮热,内热消渴,肠燥便秘。
五味子:五味子为木兰科植物五味子Schisandra chinensis(Turcz.)Baill.或华中五味子Schisandra sphenanthera Rehd.et Wils.的干燥成熟果实。敛肺,滋肾,生津,收汗,涩精。治肺虚喘咳,口干作渴,自汗,盗汗,劳伤羸瘦,梦遗滑精,久泻久痢。
生鸡内金:雉科动物家鸡Gallusgallusdomesticus Brisson的干燥沙囊内壁。归脾、胃、小肠、膀胱经,用于食积不消,呕吐泻痢,小儿疳积,遗尿,遗精,石淋涩痛,胆胀胁痛。
麦冬:(学名:Ophiopogon japonicus(Linn.f.)Ker-Gawl.)百合科沿阶草属多年生常绿草本植物的小块根。有生津解渴、润肺止咳之效,麦冬主要含沿阶草苷、甾体皂苷、生物碱、谷甾醇、葡萄糖、氨基酸、维生素等,具有抗疲劳、清除自由基、提高细胞免疫功能以及降血糖的作用。另外,麦冬有镇静、催眠、抗心肌缺血、抗心律失常、抗肿瘤等作用,尤其对增进老年人健康具有多方面功效。还有促进胰岛细胞功能恢复、增加肝糖原、降低血糖的作用。
生地:别名生地黄,野地黄、山烟根等,为玄参科植物地黄的块根。归心,肝,肾经。既有止血、又有抗凝血作用,抗真菌作用,还具有促进肾上腺皮质激素的合成的作用。主男子五劳七伤,女子伤中、胞漏、下血,破恶血、溺血,利大小肠,去胃中宿食,饱力断绝,补五脏内伤不足,通血脉,益气力,利耳目。
香菇:Lentinus edodes(Berk.)sing,为侧耳科植物香蕈,富含维生素B群、铁、钾、维生素D原(经日晒后转成维生素D)、味甘,性平,香菇中麦角甾醇含量很高,对防治佝偻病有效;香菇多糖(β~1,3葡聚糖)能增强细胞免疫能力;香菇含有六大酶类的40多种酶,可以纠正人体酶缺乏症;香菇中的脂肪所含脂肪酸,对人体降低血脂有益。
草菇:Volvariella volvacea(Bull.:Fr.)Sing.又名兰花菇、苞脚菇。草菇性寒、味甘、微咸、无毒。主治暑热烦渴;体质虚弱;头晕乏力;高血压,具有消食祛热,补脾益气,清暑热,滋阴壮阳,增加乳汁,防止坏血病,促进创伤愈合,护肝健胃,增强人体免疫力的功效。
金针菇:名毛柄金钱菌,又称毛柄小火菇、构菌、朴菇、冬菇、朴菰、冻菌、金菇、智力菇等,英文为:“Enoki Mushroom”。植物学名为Flammulina velutiper(Fr.)Sing,含有一种叫朴菇素的物质,有增强机体对癌细胞的抗御能力,常食金针菇还能降胆固醇,预防肝脏疾病和肠胃道溃疡,增强机体正气,防病健身。促进体内新陈代谢,有利于食物中各种营养素的吸收和利用。
中医学认为,糖尿病,主要是由于素体阴虚,五脏柔弱,复因饮食不节,过食肥甘,情志失调,劳欲过度,而导致肾阴亏虚,肺胃燥热;病机重点为阴虚燥热,而以阴虚为本,燥热为标;病延日久,阴损及阳,阴阳俱虚;阴虚燥热,耗津灼液使血液粘滞,血行涩滞而成瘀。
本发明的口含制品,其中的其中红景天、生地:具有补气清肺,益智养心,收涩止血,散瘀消肿,可调节新陈代谢、神经乏力的症状,起到强壮五脏、扶正固本的作用;蜂胶,性平,味苦、辛、微甘,有润肤生肌,消炎止痛的功效,可治疗胃溃疡、口腔溃疡、烧烫伤、皮肤裂痛,可预防和治疗糖尿病并发的炎症,促进机体修复;东革阿里、五味子、花粉,能够促进人体分泌更多的荷尔蒙、雄性激素、黄体酮等,可调节人体内分泌、使人体自身阴阳平衡、增强血液循环和新陈代谢,增加肾动力,兼具修复阴阳俱虚情志失调的症状;海带、紫菜:可软坚化痰,祛湿止痒,清热行水,补肾养心,调节肾水代谢机能,以及肝糖代谢能力。葛根、麦冬、金针菇子实体、茶树菇子实体:能有效地增强机体的生物活性,促进体内新陈代谢,提高免疫力,缓解疲劳现象;有利于各种营养物质吸收利用、抑制血脂升高,降低胆固醇,防治心脑血管疾病,促进胰岛细胞功能恢复、增加肝糖原、降低血糖的作用,预防糖尿病的发生或继续,也能减轻糖尿病并发的肝、肾,心脑血管损伤并发症;葛根有生津止渴、止泻的功能,能降低血糖,并有解热及雌激素样作用并能改善高血压糖尿病病人的头晕、头痛等症状。生黄芪,主治气血虚弱、自汗、久泻脱肛、子宫脱垂、肾炎浮肿、蛋白尿、糖尿病、慢性溃疡等症,临床用来治疗高血压和急慢性肾炎。山药、生地、生鸡内金:具有滋养强壮,助消化,敛虚汗,止泻之功效,有利于调节患者五脏协调代谢平衡。
本发明的口含制品,通过发酵,使中药中的多糖与香菇、草菇、金针菇的多种多糖发生綴合,使本发明的药物中含有更高含量、更多种类的多糖綴合物,能够显著增强机体免疫力,经过发酵产生的丰富的多糖具有类似非特异性免疫作用,诱导机体恢复正常代谢平衡,预付或治疗糖尿病,或降低并发症的发生率。
本领域技术人员,可以根据本发明的内容得到本发明的制品,并且将该制品作为有效成分,添加药学上可接受的辅助成分,如赋形剂、悬浮剂、缓释剂、调味剂等从而制成各种剂型的口含药物。这些药物都属于本发明的同一个构思,因此也在此请求给予保护。
药效试验数据显示,本发明的口含制品能显著降低四氧嘧啶、肾上腺素诱发的高血糖,并使低下的肝糖原回升,能抑制葡萄糖的吸收,对葡萄糖引起的血糖升高有显著的奶糖作用,保护胰岛细胞,可用于治疗糖尿病。并且无任何毒副作用。临床观察统计,本发明的口含制品能够显著改善或消除糖尿病患者的并发症,并代替西药,使患者逐渐对西药以及对本发明的制品都不再有依赖性。
具体实施方式
以下通过具体实施例描述本发明的制品及其制备工艺。
一、材料:
金针菇试管母种:购自中国农业微生物菌种保藏管理中心,保藏编号50007规格:试管斜面种(试管规格18mm×180mm,约40毫升)。购买到的或现有技术中记载的其它金针菇菌株也适用本发明。申请人实验室亦有亦有保存,并制备成试管菌丝母种,自申请日起二十年可向公众发放用于实验研究
香菇试管母种:购自中国农业微生物菌种保藏管理中心,保藏编号50023规格:试管斜面种(试管规格18mm×180mm,约40毫升)。购买到的或现有技术中记载的其它香菇菌株也适用本发明。申请人实验室亦有亦有保存,并制备成试管菌丝母种,自申请日起二十年可向公众发放用于实验研究
草菇试管母种:购自中国农业微生物菌种保藏管理中心,保藏编号51595规格:试管斜面种(试管规格18mm×180mm,约40毫升)。购买到的或现有技术中记载的其它草菇菌株也适用本发明。申请人实验室亦有亦有保存,并制备成试管菌丝母种,自申请日起二十年可向公众发放用于实验研究
中国农业微生物菌种保藏管理中心,联系方式010-68918636 010-68918651 010-68918683accc@caas.ac.cn。上述母种,申请人实验室亦有保存,并制备成试管菌丝母种,自申请日起二十年可向公众发放用于实验研究。用于本发明的上述母种也可以是商购途径得到,没有特别要求。
中药原料药在一般中药房可购买到。
二、富氢水:日田天领水。
三、设备:
超高压锅:DEPCOA—500,采用超高压灭菌技术(Ultra-highpressureprocessing),简称UHP;高压食品加工技术(highpressure processing)。
发酵罐:为专利号03270560.3,名称为“食用菌液体菌种培养罐的罐盖及培养罐”的实用新型专利中记载的发酵罐。
注射器:专利号200320126960.X,名称为“食用菌液体注射杆及包含该注射杆的注射器”的实用新型专利中记载的注射器。
四:准备母种液:
1)在18L富氢水中加入硫酸镁20g,磷酸氢二钾50g,磷酸二氢钾50g,蔗糖250g,淀粉250g,加富氢水定容至20L。
2)将液体培养基1注入500ml玻璃瓶内,每瓶400ml,一共得50瓶,置入手提高压锅内在0.012MP/cm2,30min,取出后冷却至28℃~34℃,放入超净工作台内,制得液体培养基。
3)将工具、器皿以及液体培养基放入超净工作台内,用30g高锰酸钾置入盛有50%福尔马林30ml的器皿中,接种用的勾、耙、针、刀放入该器皿中灭菌30min。
4)将试管内母种,切成3份,每份分别接入400ml/瓶的液体培养基内,静置120min-150min。
5)在摇床上以20次/min,振荡72-96小时,镜检无杂菌,即得母种液。
实施例1.用于糖尿病的1号口含制品
配比好的原料药1:红景天20、蜂胶10,东革阿里100,海带10,紫菜10,金针菇子实体10,茶树菇子实体10,葛根10,生黄芪10,生山药10,花粉10,知母10,五味子10,生鸡内金10,麦冬10,生地10;
步骤1.水,采用超高压锅在30℃、600mpa环境下灭活10分钟,完成后其中40升通过无菌硅胶管道注入无菌发酵罐内备用。
步骤2.提取中药的水提取液:
配比好的原料药装在100目滤网中,在超高压锅加入水和配比好的原料药,重量比为4:1;
在30℃、800mpa环境下处理30分钟,提取中药原液。
步骤3:共发酵
将提取中药的水提取液注入步骤1准备好的已注入40升富氢水的发酵灌中。
再依次注入金针菇、草菇、香菇的母种液各7升进行发酵。发酵时间到为72小时时,检测有效固体物,含量达80g/L以上时放罐停止发酵。
步骤4.浓缩:放罐后,进入醇沉提取罐,用冷水浸提渗滤,将提取液沉淀,利用多糖不溶于乙醇的性质,使多糖从提取液中沉淀出来,在≦30℃低温下浸制5小时,再进行≦55℃烘干或喷雾干燥得成品。
实施例2.用于糖尿病的2号口含制品
配比好的原料药2:红景天15,蜂胶12,东革阿里80,海带12,紫菜12,金针菇子实体8,茶树菇子实体12,葛根8,生黄芪8,生山药10,花粉10,知母12,五味子8,生鸡内金12,麦冬9,生地10;
步骤1.富氢水(日田天领水),采用超高压锅在30℃、600mpa环境下灭活10分钟,完成后其中50升通过无菌硅胶管道注入无菌发酵罐内备用。
步骤2.提取中药的水提取液:
配比好的原料药装在100目滤网中,在超高压锅加入富氢水和配比好的原料药,重量比为3:1;
在28℃、800mpa环境下处理50分钟,提取中药原液。
步骤3:共发酵
将提取中药的水提取液注入步骤1准备好的已注入40升富氢水的发酵灌中。
再依次注入金针菇、草菇、香菇的母种液各7升进行发酵。发酵时间到为72小时时,检测有效固体物,含量达80g/L以上时放罐停止发酵。
步骤4.浓缩:放罐后,进入醇沉提取罐,用冷水浸提渗滤,将提取液沉淀,利用多糖不溶于乙醇的性质,使多糖从提取液中沉淀出来,在≦30℃低温下浸制5小时,再进行≦55℃烘干或喷雾干燥得成品。
实施例3.用于糖尿病的3号口含制品
配比好的原料药3:红景天25,蜂胶8,东革阿里110,海带8,紫菜8,金针菇子实体12,茶树菇子实体10,葛根10,生黄芪12,生山药8,花粉8,知母8,五味子10,生鸡内金8,麦冬8,生地8;
步骤1.富氢水(日田天领水),采用超高压锅在30℃、600mpa环境下灭活10分钟,完成后其中30升通过无菌硅胶管道注入无菌发酵罐内备用。
步骤2.提取中药的水提取液:
配比好的原料药装在100目滤网中,在超高压锅加入富氢水和配比好的原料药,重量比为6:1;
在32℃、800mpa环境下处理35分钟,提取中药原液。
步骤3:共发酵
将提取中药的水提取液注入步骤1准备好的已注入45升富氢水的发酵灌中。
再依次注入金针菇、草菇、香菇的母种液各6升进行发酵。发酵时间到为72小时时,检测有效固体物,含量达80g/L以上时放罐停止发酵。
步骤4.浓缩:放罐后,进入醇沉提取罐,用冷水浸提渗滤,将提取液沉淀,利用多糖不溶于乙醇的性质,使多糖从提取液中沉淀出来,在≦30℃低温下浸制5小时,再进行≦55℃烘干或喷雾干燥得成品。
实施例4.用于糖尿病的4号口含制品
配比好的原料药4:红景天18,蜂胶9,东革阿里90,海带9,紫菜9,金针菇子实体9,茶树菇子实体8,葛根12,生黄芪9,生山药12,花粉12,知母10,五味子12,生鸡内金9,麦冬9,生地12。
步骤1.水,采用超高压锅在30℃、600mpa环境下灭活10分钟,完成后其中50升通过无菌硅胶管道注入无菌发酵罐内备用。
步骤2.提取中药的水提取液:
配比好的原料药装在100目滤网中,在超高压锅加入富氢水和配比好的原料药,重量比为5:1;
在35℃、800mpa环境下处理30分钟,提取中药原液。
步骤3:共发酵
将提取中药的水提取液注入步骤1准备好的已注入30升富氢水的发酵灌中。
再依次注入金针菇、草菇、香菇的母种液各8升进行发酵。发酵时间到为72小时时,检测有效固体物,含量达80g/L以上时放罐停止发酵。
步骤4.浓缩:放罐后,进入醇沉提取罐,用冷水浸提渗滤,将提取液沉淀,利用多糖不溶于乙醇的性质,使多糖从提取液中沉淀出来,在≦30℃低温下浸制5小时,再进行≦55℃烘干或喷雾干燥得成品。
药效观察
实验例1.本发明的口含制品对四氧嘧啶诱发小鼠血糖升高的影响
1.实验材料
昆明种小鼠,体重20-25克,雄性;
降糖灵:作为阳性对照,江苏省金坛市制药厂。
实施例1-4中制备得到的浓缩之前的发酵产物。
四氧嘧啶,美国sigma。
2.方法
随机取10只为正常组,其余小鼠静脉注册四氧嘧啶65mg/kg。根据血糖值分为5组,每组10只,其中一组作为模型对照组,另外四组分别按0.1mg/10体重经口给予实施例1-4任一所述的口含制品,25,50,100mg/kg,以及降糖灵75mg/kg,正常组和模型对照组给予等体积蒸馏水,连续7天。取血分离血清,以葡萄糖氧化酶法测定血糖,并对胰腺进行病理组织学检测。
3.结果:
与正常组相比,模型对照组小鼠血糖极显著升高(395.5±94.6mg/dl)。
和模型对照比相比,口含制品组的低剂量组有降低高血糖的趋势,而中、高剂量组和降糖灵组极显著地降低高血糖,口含制品的降糖作用呈现计量依赖性。50,100mg/kg组的降糖水平分别为185.4±65.2mg/dl,105.5±7.7mg/dl,降糖作用显著强于降糖灵75mg/kg(265.4±85.8mg/dl)。
病理组织学检测结果表明,与模型对照组对比,口含制品各剂量组的胰岛数量和胰岛内细胞数量均明显增加,而降糖灵组的胰岛数量和胰岛内细胞数量仅仅略微增加。说明本发明的口含制品明显由于降糖灵。
实验例2.本发明的口含制品对葡萄糖诱发小鼠血糖升高的影响
1.实验材料
昆明种小鼠,体重20-25克,雄性;
降糖灵:作为阳性对照,江苏省金坛市制药厂
实施例1-4中制备得到的浓缩之前的发酵产物。
50%葡萄糖注射液。
2.方法
取84只小鼠,随机分为6组,其中4组分别按0.1ml/10g体重经口给予植物提取物25,50,100mg/kg和降糖灵75mg/kg,正常组和模型对照组给予等体积蒸馏水,连续7天。
除正常组外,其余各组腹腔注射葡萄糖2g/kg,正常组注射等体积生理盐水,注射后30,60,90,120分钟,测定血糖(葡萄糖氧化酶法测定血糖)。
3.结果:
与正常组相比,模型对照组小鼠在腹腔注射葡萄糖后30,60,90,120分钟,血糖显著升高。
和模型对照比相比,口含制品组的中、低剂量组在腹腔注射葡萄糖后30,60,90,显著降低葡萄糖诱发的高血糖;
高剂量组和降糖灵组极显著地降低葡萄糖诱发的高血糖高血糖。
本发明口含制品的降糖作用呈现计量依赖性。
本发明口含制品组100mg/kg组有极显著的降糖作用,90分钟为128.4±10.2mg/dl,正常组104.5±13.1mg/dl,模型对照组:159.6±15.5mg/dl)与降糖灵75mg/kg(132.5±13.1mg/dl)相当。
实验例3.本发明的肾上腺素诱发小鼠血糖升高的影响
1.实验材料
昆明种小鼠,体重20-25克,雄性;
优降糖:天津太平洋制药有限公司。
实施例1-4中制备得到的浓缩之前的发酵产物。
盐酸肾上腺素注射液(武汉制药集团股份有限公司)
葡萄糖测定试剂盒(上海荣盛生物技术有限公司)
肝糖原测定试剂盒(南京建成生物工程研究所)
2.方法
取84只小鼠,随机分为6组,其中4组分别按0.1ml/10g体重经口给予植物提取物25,50,100mg/kg和优降糖10mg/kg,正常组和模型对照组给予等体积蒸馏水,连续7天。除正常组外,其余各组腹腔肾上腺素0.2g/kg,正常组注射等体积生理盐水,注射后30分钟,测定血糖(葡萄糖氧化酶法测定血糖),同时取肝脏以蒽酮法测定肝糖原。
3.结果:
与正常组相比,模型对照组小鼠在腹腔注射葡萄糖后30,60,90,120分钟,血糖显著升高。
和模型对照比相比,制品组显著降低葡萄糖诱发的高血糖(25mg/kg,165.5±13.1mg/dl);同时模型对照组小鼠肝糖原极显著降低。和模型对照比相比,制品组及显著升高肝糖原含量(25mg/kg,5.2±1.2mg/g肝组织);
以上药效研究结果表明,本发明的制品能显著降低四氧嘧啶、肾上腺素诱发的高血糖,并使低下的肝糖原回升,能抑制葡萄糖的吸收,对葡萄糖引起的血糖升高有显著的奶糖作用,保护胰岛细胞,可用于治疗糖尿病。
实验例4.毒性实验
取正常小鼠20只,分别口服和静脉注射实施例1-4中所得的发酵产物(给予允许大最大浓度和体积)方式急性毒性实验。
结果:无动物死亡,健康状况良好。14天之后处死小鼠,主要脏器均无异常。
本发明的口服制品为常用中药原料药和药食同源的食用菌每种发酵而得,原料本身无毒副作用,采用发酵的过程更是去除了药物中药性生猛的成分。使得药物更为安全无毒副作用。
临床观察实验例
2012年5月2016年2月收治糖尿病患者共48余例。
年龄45-55岁之间,其中41例病程10-15年,持续以注射胰岛素,口含二甲双胍,利血平片。7例为新诊断为糖尿病,症状包括:糖尿病足15例,视网膜病变32例,口干48例、多饮48例、下肢浮肿39例、精神萎靡48例,视力不清36例等。
随机提供本发明的口含制品,三次每次2g,餐后服用,一次见效。可在餐后两小時测血糖来证实,14天一个疗程,4个疗程后,随访,患者自述结合查体,治疗结果统计如下:
糖尿病足15例显著改善;视网膜病变21例显著改善,11例症状消除;口干48例症状消除;多饮48例症状消除;下肢浮肿39例症状消除;精神萎靡48例改善;视力不清29例改善,10例消除症状,41例的胰岛素用量明显减少、口服西药量减半以上,其中11例通过饮食调节,结合服用本发明的口含制品,已经摆脱对西药的依赖,后续疗程中,本发明的制品也用量减半,持续服用4-5个,逐渐不再需要服用任何药物,仅需要饮食注意即可。
Claims (10)
1.一种用于糖尿病的口制品,其特征在于:
是以下原料药的水提取液与香菇、草菇、金针菇母种液进行共发酵所得的产物;
所述原料药具有以下重量份配比:红景天15-25,蜂胶8-12,东革阿里80-110,海带8-12,紫菜8-12,金针菇子实体8-12,茶树菇子实体8-12,葛根8-12,生黄芪8-12,生山药8-12,花粉8-12,知母8-12,五味子8-12,生鸡内金8-12,麦冬8-12,生地8-12。
2.根据权利要求1所述的口含制品,其特征在于:
所述原料药的水提取液是采用富氢水为提取溶剂,所述富氢水为日田天领水。
3.根据权利要求1所述的口含制品,其特征在于:所述原料药具有以下任一组重量份配比:
红景天20、蜂胶10,东革阿里100,海带10,紫菜10,金针菇子实体10,茶树菇子实体10,葛根10,生黄芪10,生山药10,花粉10,知母10,五味子10,生鸡内金10,麦冬10,生地10;
红景天15,蜂胶12,东革阿里80,海带12,紫菜12,金针菇子实体8,茶树菇子实体12,葛根8,生黄芪8,生山药10,花粉10,知母12,五味子8,生鸡内金12,麦冬9,生地10;
红景天25,蜂胶8,东革阿里110,海带8,紫菜8,金针菇子实体12,茶树菇子实体10,葛根10,生黄芪12,生山药8,花粉8,知母8,五味子10,生鸡内金8,麦冬8,生地8;
红景天18,蜂胶9,东革阿里90,海带9,紫菜9,金针菇子实体9,茶树菇子实体8,葛根12,生黄芪9,生山药12,花粉12,知母10,五味子12,生鸡内金9,麦冬9,生地12。
4.一种用于制备糖尿病口含制品的原料组合物,其特征在于:包括A原料药,具有以下重量份配比:红景天15-25,蜂胶8-12,东革阿里80-110,海带8-12,紫菜8-12,金针菇子实体8-12,茶树菇子实体8-12,葛根8-12,生黄芪8-12,生山药8-12,花粉8-12,知母8-12,五味子8-12,生鸡内金8-12,麦冬8-12,生地8-12。
5.根据权利要求4所述的组合物,特征在于:所述A原料药,具有以下任一组重量份配比:
红景天20、蜂胶10,东革阿里100,海带10,紫菜10,金针菇子实体10,茶树菇子实体10,葛根10,生黄芪10,生山药10,花粉10,知母10,五味子10,生鸡内金10,麦冬10,生地10;
红景天15,蜂胶12,东革阿里80,海带12,紫菜12,金针菇子实体8,茶树菇子实体12,葛根8,生黄芪8,生山药10,花粉10,知母12,五味子8,生鸡内金12,麦冬9,生地10;
红景天25,蜂胶8,东革阿里110,海带8,紫菜8,金针菇子实体12,茶树菇子实体10,葛根10,生黄芪12,生山药8,花粉8,知母8,五味子10,生鸡内金8,麦冬8,生地8;
红景天18,蜂胶9,东革阿里90,海带9,紫菜9,金针菇子实体9,茶树菇子实体8,葛根12,生黄芪9,生山药12,花粉12,知母10,五味子12,生鸡内金9,麦冬9,生地12。
6.权利要求1-3任一所述的用于糖尿病的口含制品的制备方法,包括如下步骤:
(1)制备原料药的水提取液;
(2)原料药的水提取液与香菇母种液、草菇母种液和金针菇母种液进行共发酵得到发酵产物;
其特征在于,所述原料药的水提取液的提取工艺如下:在提取容器中,加入富氢水和原料药;富氢水与所述原料药重量比例为3-6:1,在25-35℃、800mpa环境下提取30-50分钟得到所述原料药的水提取液。
7.根据权利要求6所述的制备方法,其特征在于:
富氢水与所述原料药重量比例为4-5:1,在28-32℃、800mpa环境下提取30-40分钟得到所述原料药的水提取液。
8.根据权利要求6所述的制备方法,其特征在于:所述进行共发酵是指在发酵罐中,按30-50:30-50:5-10:5-10:5-10的体积比加入所述原料药的水提取液、富氢水、香菇母种液、草菇母种液和金针菇母种液,发酵到有效固体物含量达80g/L以上时放罐。
9.根据权利要求8所述的制备方法,其特征在于:
按35-45:35-45:6-8:6-8:6-8的体积比加入所述原料药的水提取液、富氢水、香菇母种液、草菇母种液和金针菇母种液。
10.根据权利要求6-9任一所述的制备方法,其特征在于:
放罐后,进入醇沉提取罐,加入冷水浸提渗滤,再煮沸,滤汁去渣;其汁加4倍体积的75度酒精浸润,在≦30℃低温下浸制5小时,利用多糖不溶于乙醇的性质,使多糖从提取液中沉淀出来,升温至50摄氏度回收酒精后,对沉淀再进行≦55℃烘干或喷雾干燥,制得成品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711175472.0A CN107898920A (zh) | 2017-11-22 | 2017-11-22 | 一种用于糖尿病的口含制品与制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711175472.0A CN107898920A (zh) | 2017-11-22 | 2017-11-22 | 一种用于糖尿病的口含制品与制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107898920A true CN107898920A (zh) | 2018-04-13 |
Family
ID=61846953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711175472.0A Pending CN107898920A (zh) | 2017-11-22 | 2017-11-22 | 一种用于糖尿病的口含制品与制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107898920A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108403877A (zh) * | 2018-05-24 | 2018-08-17 | 高承峰 | 一种具有减肥、改善睡眠的中药组合物及其制备方法 |
| CN113712992A (zh) * | 2021-09-02 | 2021-11-30 | 武汉英纽林生物科技有限公司 | 含菊粉的益生元与富氢水联用在制备血糖控制药物中的应用 |
| CN119015305A (zh) * | 2024-10-29 | 2024-11-26 | 江苏康缘药业股份有限公司 | 红景天多糖、制备方法及其在制备治疗慢性肾炎药物中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104082740A (zh) * | 2014-06-25 | 2014-10-08 | 北京赛升药业股份有限公司 | 一种具有干预或改善糖尿病的组合物及其制备方法 |
| CN107158231A (zh) * | 2017-06-07 | 2017-09-15 | 马凯 | 一种预防和控制糖尿病的益生菌发酵中草药的组合物 |
-
2017
- 2017-11-22 CN CN201711175472.0A patent/CN107898920A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104082740A (zh) * | 2014-06-25 | 2014-10-08 | 北京赛升药业股份有限公司 | 一种具有干预或改善糖尿病的组合物及其制备方法 |
| CN107158231A (zh) * | 2017-06-07 | 2017-09-15 | 马凯 | 一种预防和控制糖尿病的益生菌发酵中草药的组合物 |
Non-Patent Citations (2)
| Title |
|---|
| 《健康大讲堂》编委会主编: "《药膳王》", 31 January 2013, 黑龙江科学技术出版社 * |
| 定明阳: "玉液汤治疗糖尿病50例报告", 《实用中医内科杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108403877A (zh) * | 2018-05-24 | 2018-08-17 | 高承峰 | 一种具有减肥、改善睡眠的中药组合物及其制备方法 |
| CN113712992A (zh) * | 2021-09-02 | 2021-11-30 | 武汉英纽林生物科技有限公司 | 含菊粉的益生元与富氢水联用在制备血糖控制药物中的应用 |
| CN119015305A (zh) * | 2024-10-29 | 2024-11-26 | 江苏康缘药业股份有限公司 | 红景天多糖、制备方法及其在制备治疗慢性肾炎药物中的应用 |
| CN119015305B (zh) * | 2024-10-29 | 2025-01-28 | 江苏康缘药业股份有限公司 | 红景天多糖、制备方法及其在制备治疗慢性肾炎药物中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102919836B (zh) | 一种降糖、降压、降脂、通便养颜、减肥、抗疲劳保健品及其生产工艺 | |
| CN103719498B (zh) | 一种提高免疫力的黄精保健茶及其制备方法 | |
| CN103734428B (zh) | 一种提高免疫力的女贞子保健茶及其制备方法 | |
| CN106943586A (zh) | 一种男性保健壮阳制剂生产方法 | |
| CN108524814A (zh) | 一种用于降低血糖的中药组合物及其制备方法 | |
| KR100947278B1 (ko) | 하엽 추출물을 주성분으로 하는 탄수화물 및 지방 흡수억제 활성을 가지는 생약 조성물과 이의 제조 방법 | |
| CN104305205A (zh) | 一种提高免疫力的菟丝子口服液及其制备方法 | |
| CN103405657B (zh) | 一种治疗咳嗽的药物及其制备方法 | |
| CN107898920A (zh) | 一种用于糖尿病的口含制品与制备方法 | |
| CN101904919B (zh) | 一种治疗痔疮的药物及其制备方法 | |
| CN104489172A (zh) | 一种提高免疫力的刺五加保健茶及其制备方法 | |
| NL2037306B1 (en) | A nutritional product for clearing and protecting the lungs and a preparation method thereof | |
| CN106924548A (zh) | 一种缓解疲劳的药物及制备方法 | |
| CN103405631A (zh) | 用于肺癌患者的制品及其制备方法 | |
| CN102028718A (zh) | 一种解酒毒的药物及其制备方法 | |
| CN1676036A (zh) | 灵芝金刚根保健食品及其制备方法 | |
| CN102091228B (zh) | 一种治疗失眠的药物及其制备方法 | |
| CN105727253A (zh) | 保肝清毒预防治疗肝脏及相关代谢性疾病的组合物及制备方法 | |
| CN102133283B (zh) | 一种治疗便秘的药物及其制备方法 | |
| KR20100024244A (ko) | 혈당강하 효과가 증가된 한방청국장의 제조방법 | |
| CN104893915A (zh) | 滋阴补阳、补中益气的保健酒及其制备方法 | |
| CN104258260B (zh) | 一种肉苁蓉醇提取物、制备方法及其用途 | |
| CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
| CN107125751A (zh) | 龟粉、制备方法及其应用 | |
| CN104673573A (zh) | 具有防治糖尿病功效的葡萄酒及制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180413 |